Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373372 | 1.00 | ALDH1A1 (0.30) | ALDH1A1HSD17B10 | |
| SCHEMBL135065 | 0.96 | — | — | |
| SCHEMBL2154851 | 0.65 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL138530 | 0.59 | — | — | |
| SCHEMBL18430746 | 0.59 | — | — | |
| SCHEMBL31178563 | 0.59 | — | — | |
| SCHEMBL12079166 | 0.56 | ALDH1A1 (0.36) | ALDH1A1HSD17B10 | |
| SCHEMBL5924608 | 0.56 | — | — | |
| SCHEMBL18636380 | 0.56 | ALDH1A1 (0.36) | ALDH1A1HSD17B10 | |
| SCHEMBL1977943 | 0.56 | ALDH1A1 (0.36) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342295-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | THE UNIVERSITY OF MANCHESTER (GB) | 2024-10-17 | — | — | US | disclosed |
| US-20240269308-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024138000-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138000-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4268856-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022145419-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| EP-3991792-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021125279-A1 | CHEMICALLY CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021125255-A1 | NOVEL CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| EP-3808783-A1 | NOVEL CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-2314566-A1 | Process for the functionalization of biological molecules | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2011007352-A2 | INTRALUMINAL POLYMERIC DEVICES FOR THE TREATMENT OF ANEURYSMS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010106245-A1 | NOVEL BIFUNCTIONAL MOLECULES COMPRISING A CYCLOALKYNE OR HETEROCYCLOALKYNE GROUP AND A REDOX GROUP | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106245-A1 | NOVEL BIFUNCTIONAL MOLECULES COMPRISING A CYCLOALKYNE OR HETEROCYCLOALKYNE GROUP AND A REDOX GROUP | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106243-A1 | NOVEL SILANE COMPOUNDS HAVING A CYCLIC CARBON CHAIN INCLUDING AN ALKYNE FUNCTION FOR FUNCTIONALISING SOLID SUBSTRATES AND IMMOBILISING BIOLOGICAL MOLECULES ON SAID SUBSTRATES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106246-A1 | METHOD FOR SURFACE FUNCTIONALISATION BY DISUBSTITUTED ALKYNES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-09-23 | — | — | WO | disclosed |
| US-20100200813-A1 | SEMICONDUCTOR NANOCRYSTALS | COMMISSARIAT A L' ENERGIE ATOMIQUE (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2161239-A1 | Semiconductor nanocrystals | Commissariat à l'Energie Atomique (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269308-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | TOP1, TOP2A, QPCT | ALDH1A1 731/4885HSD17B10 1457/4885 |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | ALDH1A1 3718/4885HSD17B10 3752/4885 |
| US-20240342295-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | CHRM2, CMBL, H1-0 | ALDH1A1 2786/4885HSD17B10 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.